Jeremy M Shefner1, Dawei Liu2, Melanie L Leitner2, David Schoenfeld2, Donald R Johns2, Toby Ferguson2, Merit Cudkowicz2. 1. From the Department of Neurology (J.M.S.), Barrow Neurological Institute, Phoenix, AZ; Biogen (D.L., M.L.L., D.R.J., T.F.), Cambridge; and Department of Neurology (D.S., M.C.), Massachusetts General Hospital, Boston. Jeremy.Shefner@DignityHealth.org. 2. From the Department of Neurology (J.M.S.), Barrow Neurological Institute, Phoenix, AZ; Biogen (D.L., M.L.L., D.R.J., T.F.), Cambridge; and Department of Neurology (D.S., M.C.), Massachusetts General Hospital, Boston.
Abstract
OBJECTIVE: To study the attributes of quantitative strength testing using hand-held dynamometry (HHD) as an efficacy measure in 2 large phase 3 amyotrophic lateral sclerosis (ALS) trials. METHODS: In the phase 3 trials of ceftriaxone and dexpramipexole, 513 and 943 patients, respectively, were enrolled in double-blind, randomized, placebo-controlled trials with planned follow-up of at least 1 year. Patients were studied every 3 months in the ceftriaxone study and every 2 months in the dexpramipexole study. Evaluators of HHD were trained and had to show evidence of adequate performance of strength testing; the testing paradigm involved testing 9 muscle groups in the upper and lower extremity bilaterally. Neither drug significantly affected any outcome measure. Strength measurements were evaluated by individual muscle and by megascores, which averaged scaled strength measures to produce an overall measure of muscle strength. RESULTS: A measure combining rate of decline with both within- and between-patient variabilities of measurement, the coefficient of variation for rate of change, was calculated, and showed that HHD overall performed slightly less well than Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) but better than vital capacity. Individual muscles were highly correlated to the identical muscles on the contralateral side, as well as to other muscles in the same body region. Strength decline was correlated both with ALSFRS-R and vital capacity. CONCLUSION: Quantitative strength testing using HHD is a reliable and reproducible measure of decline in ALS.
OBJECTIVE: To study the attributes of quantitative strength testing using hand-held dynamometry (HHD) as an efficacy measure in 2 large phase 3 amyotrophic lateral sclerosis (ALS) trials. METHODS: In the phase 3 trials of ceftriaxone and dexpramipexole, 513 and 943 patients, respectively, were enrolled in double-blind, randomized, placebo-controlled trials with planned follow-up of at least 1 year. Patients were studied every 3 months in the ceftriaxone study and every 2 months in the dexpramipexole study. Evaluators of HHD were trained and had to show evidence of adequate performance of strength testing; the testing paradigm involved testing 9 muscle groups in the upper and lower extremity bilaterally. Neither drug significantly affected any outcome measure. Strength measurements were evaluated by individual muscle and by megascores, which averaged scaled strength measures to produce an overall measure of muscle strength. RESULTS: A measure combining rate of decline with both within- and between-patient variabilities of measurement, the coefficient of variation for rate of change, was calculated, and showed that HHD overall performed slightly less well than Amyotrophic Lateral Sclerosis Functional Rating Scale-revised (ALSFRS-R) but better than vital capacity. Individual muscles were highly correlated to the identical muscles on the contralateral side, as well as to other muscles in the same body region. Strength decline was correlated both with ALSFRS-R and vital capacity. CONCLUSION: Quantitative strength testing using HHD is a reliable and reproducible measure of decline in ALS.
Authors: J M Shefner; M L Watson; L Simionescu; J B Caress; T M Burns; N J Maragakis; M Benatar; W S David; K R Sharma; S B Rutkove Journal: Neurology Date: 2011-06-15 Impact factor: 9.910
Authors: Swati P Aggarwal; Lorne Zinman; Elizabeth Simpson; Jane McKinley; Katherine E Jackson; Hanika Pinto; Petra Kaufman; Robin A Conwit; David Schoenfeld; Jeremy Shefner; Merit Cudkowicz Journal: Lancet Neurol Date: 2010-04-01 Impact factor: 44.182
Authors: Merit E Cudkowicz; Sarah Titus; Marianne Kearney; Hong Yu; Alexander Sherman; David Schoenfeld; Douglas Hayden; Amy Shui; Benjamin Brooks; Robin Conwit; Donna Felsenstein; David J Greenblatt; Myles Keroack; John T Kissel; Robert Miller; Jeffrey Rosenfeld; Jeffrey D Rothstein; Ericka Simpson; Nina Tolkoff-Rubin; Lorne Zinman; Jeremy M Shefner Journal: Lancet Neurol Date: 2014-10-05 Impact factor: 44.182
Authors: Vincent Meininger; Gilbert Bensimon; Walter R Bradley; Benjamin Brooks; Patrice Douillet; Andrew A Eisen; Lucette Lacomblez; P Nigel Leigh; Wim Robberecht Journal: Amyotroph Lateral Scler Other Motor Neuron Disord Date: 2004-06
Authors: Robert G Miller; Gilbert Block; Jonathan S Katz; Richard J Barohn; Vidhya Gopalakrishnan; Merit Cudkowicz; Jane R Zhang; Michael S McGrath; Elizabeth Ludington; Stan H Appel; Ari Azhir Journal: Neurol Neuroimmunol Neuroinflamm Date: 2015-04-09
Authors: Jinsy A Andrews; Lisa Meng; Sarah F Kulke; Stacy A Rudnicki; Andrew A Wolff; Michael E Bozik; Fady I Malik; Jeremy M Shefner Journal: JAMA Neurol Date: 2018-01-01 Impact factor: 18.302
Authors: Fabiola De Marchi; James D Berry; James Chan; Sarah Caldwell; Amy Ellrodt; Jennifer Scalia; Katherine Burke; Ton Fang; Rachel Clark Sisodia; Lee H Schwamm; Lidia M V R Moura; Sabrina Paganoni Journal: J Neurol Date: 2020-03-03 Impact factor: 4.849
Authors: Srivandana Akshintala; Nashwa Khalil; Kaleb Yohay; Alona Muzikansky; Jeffrey Allen; Anna Yaffe; Andrea M Gross; Michael J Fisher; Jaishri O Blakeley; Beverly Oberlander; Miriam Pudel; Celia Engelson; Jaime Obletz; Carole Mitchell; Brigitte C Widemann; David A Stevenson; Scott R Plotkin Journal: Neurology Date: 2021-07-06 Impact factor: 11.800
Authors: Christopher G Wier; Alexander E Crum; Anthony B Reynolds; Chitra C Iyer; Deepti Chugh; Marilly S Palettas; Patrick L Heilman; David M Kline; W David Arnold; Stephen J Kolb Journal: Muscle Nerve Date: 2018-12-21 Impact factor: 3.217